fbpx

News

Lundbeckfonden Ventures News

·         50% Less Fracture Rates with CERAMENTT with Gentamicin·         50% Less Infection Recurrence with CERAMENTT with Gentamicin·         313 Patients Total in All Groups with a Minimum of 1 Year Follow-UpLund, Sweden, (PRNEWSWIRE) October 6, 2015 - BONESUPPORTT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic...
During its first year of operations, Vtesse advances lead program into late-stage, pivotal trial and launches www.theNPCstudy.com- Goal is to establish a clear foundational data set on the safety and efficacy of VTS-270 for treatment of NPCGAITHERSBURG, Md., Sept. 28, 2015 /PRNewswire/ -- Vtesse, Inc. today announced that the first three patients have been screened for inclusion in...
CERAMENTT with Gentamicin Shown to Decrease Recurrence of Infection and Increase Bone FormationLund, Sweden, (PRNEWSWIRE) September 24, 2015 - BONESUPPORTT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced the presentation of new clinical data with the Company's platform bone void filler, CERAMENTT...
St-Priest, 9 September 2015, 7:30 AM CET - Biom'Up today announced that the company has secured EUR 31,3 million in a Series C financing round from an investment syndicate consisting of Gimv, Bpifrance Large Venture and Lundbeckfond Ventures, alongside its existing shareholders (InnoBio, Sham Innovation Santé, ACG Management, Sofimac, Mérieux Développement, OTC AM, Euroainvest and l'Améliane) and the company's...
Financing will advance Sanifit's lead drug candidate through phase IIb as a treatment for cardiovascular diseases linked to calcification and throughphase II/III for calciphylaxis.Palma de Mallorca, Spain, September 8, 2015 - Laboratoris Sanifit S.L., a clinical-stagebiopharmaceutical company, today announces that it has raised ?36.6M ($41.3M) in a SeriesC financing round. The company is focused on the...
Lund, Sweden, (PRNEWSWIRE) August 25, 2015 - BONESUPPORTT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced that its platform bone void filler, CERAMENTT with antibiotics, will have a significant presence at the upcoming 34th Annual Meeting of the European Bone & Joint Infection Society (EBJIS) taking...
Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that Envarsus® XR was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus. Envarsus® XR received marketing authorization from the FDA on July 10, 2015.
Post-Hoc Analyses of Data Show Preliminary Evidence of Overall Disease Stabilization with Improvement in Several Disease Domains
CANTERBURY, UK, 20 JULY, 2015 -- Ziarco Group Ltd., a biopharmaceutical company focusing on inflammatory skin diseases, today announced the appointment of Mike Grey as Executive Chairman of its Board of Directors, effective immediately. Mr. Grey first joined the Company's board as an independent director in December 2014. 
1 40 41 42 43 44 65

Lundbeckfonden Ventures

News

Sanifit Enhances Leadership Team with New Executive Appointments
2. June 2020
Acacia Pharma Group PLC – Acacia Pharma Announces Debt for Equity Swap with Cosmo Pharmaceuticals
2. June 2020
Acacia Pharma Group PLC – Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
8. May 2020